FindTrial
Sign In

PDS0101

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI), University of California, San Diego

Conditions

Anal CancerCervical CancerHIV (Human Immunodeficiency Virus)HPV 16 InfectionHPV Associated CancersHPV CancersOropharyngeal CancerVulvar, Vaginal, Penile, Rectal Cancer

Phase 1

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
CompletedNCT04287868
National Cancer Institute (NCI)Anal Cancer, Cervical Cancer, HPV Cancers +2
Start: 2020-06-09End: 2026-05-14Updated: 2026-06-30

Phase 2

CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
WithdrawnNCT07090174
University of California, San DiegoAnal Cancer, Cervical Cancer, HIV (Human Immunodeficiency Virus) +2
Start: 2026-04-30End: 2026-12-31Updated: 2026-08-19

Related Papers

Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers
JAMA Oncology2025-02-2015 citations
766 Phase I/II evaluation of the combination of entinostat, M9241 and bintrafusp alfa in patients with advanced HPV related malignancies
Regular and Young Investigator Award Abstracts2022-11-014 citations
695 Immune correlates associated with clinical benefit in patients with immune checkpoint refractory HPV-associated malignancies treated with triple combination immunotherapy
Regular and Young Investigator Award Abstracts2022-11-011 citations
Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies.
Journal of Clinical Oncology2022-06-0111 citations
Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.
Journal of Clinical Oncology2021-05-2020 citations
375 Expansion of HPV-16 specific T cells in patients with HPV-related cancers treated with bintrafusp alfa
Regular and Young Investigator Award Abstracts2020-11-01